MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

The US Food and Drug Administration has released draft guidance on protocol deviations, but experts say it could go further.

The EMA has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer trial in Europe to add 11 new sites.

Imvax has secured $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of IGV-001, in ndGBM individuals.

The trial combines tislelizumab and Anktiva for treating advanced or metastatic non-small cell lung cancer patients. Credit: NMK-Studio/Shutterstock. ImmunityBio has entered a supply agreement and ...